Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

MASLD/MASH Learning Center

Latest News & Blogs

Evaluation of developmental and behavioral toxicity of Resmetirom in zebrafish larvae (Danio rerio)

September 2025

Resmetirom, a promising oral THR-β agonist for treating metabolic dysfunction-associated steatohepatitis (MASH), has been studied extensively for its therapeutic efficacy, yet its effects on embryonic development remain largely unknown. This study aimed to evaluate the potential embryotoxicity of Resmetirom and investigate its impact on embryonic growth and development. We employed the zebrafish (Danio rerio) as the model organisms, and exposed embryos to varying concentrations of Resmetirom....

Read More arrow

The Ceiling Is Real: MASH Needs Combination, Not Celebration

September 2025

No abstract

Read More arrow

Heterogeneous outcomes in metabolic dysfunction-associated steatotic liver disease/steatohepatitis with type 2 diabetes: Rethinking risk and management approaches

September 2025

Gosnell and colleagues executed a large-scale cohort investigation delineating ethnic disparities in outcomes among individuals with metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH). Uncovering such heterogeneity is pivotal to optimising management and prognostication, notably for hepatocellular carcinoma, fibrotic progression, and all-cause mortality. The authors furnish granular trajectories for Hispanic vs non-Hispanic populations across the United States...

Read More arrow

Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes

September 2025

The global obesity epidemic is responsible for the rise in metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH). Metabolic bariatric surgery (MBS) is emerging as an important treatment option for patients with MASH to address both hepatic histology and their metabolic health. This scoping review aims to evaluate the impact of MBS on metabolic parameters, biomarkers, and histologic liver outcomes in adults...

Read More arrow

Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitis

September 2025

Hepatocyte apoptosis is a key feature of metabolic dysfunction-associated steatohepatitis (MASH), but the fate of apoptotic hepatocytes in MASH is poorly understood. Here, we explore the hypotheses that clearance of dead hepatocytes by liver macrophages (efferocytosis) is impaired in MASH because of low expression of the efferocytosis receptor T cell immunoglobulin and mucin domain containing 4 (TIM4; gene Timd4) by MASH liver macrophages, which then drives liver fibrosis in MASH. We show that...

Read More arrow

The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management

September 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major contributor to systemic metabolic dysfunction and is increasingly recognized as a risk enhancer for both cardiovascular disease (CVD) and chronic kidney disease (CKD). This review explores the complex interconnections between MASLD, CVD, and CKD, with emphasis on shared pathophysiological mechanisms and the clinical implications for risk assessment and management. We describe the crosstalk among the liver,...

Read More arrow

Supplementary Material for Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries

September 2025

BACKGROUND AND AIM: Although the clinical burden of MASH is well known, its economic burden is less well described. We estimated MASH's economic burden in several regions of the world including the US, Germany, Spain, France, Italy, and United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next two decades.

Read More arrow

The Proteomic Profiling of Circulating Extracellular Vesicles of Western Diet and Chemical-Induced Murine MASH Model

September 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction-associated steatohepatitis (MASH). Despite its growing burden, there are no reliable non-invasive biomarkers for tracking disease progression. In this study, we established a murine MASLD/MASH model using a high-fat diet and chemical (CCl(4)) induction. We analyzed serum-derived extracellular vesicles (EVs)...

Read More arrow

Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions

September 2025

Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that regulate gene expression in response to metabolic, hormonal, and environmental signals. These receptors play a critical role in metabolic homeostasis, inflammation, immune function, and disease pathogenesis, positioning them as key therapeutic targets. This review explores the mechanistic roles of NRs such as PPARs, FXR, LXR, and thyroid hormone receptors (THRs) in regulating lipid and glucose metabolism,...

Read More arrow

Monitoring ferroptosis in vivo: Iron-driven volatile oxidized lipids as breath biomarkers

September 2025

Ferroptosis, an iron-dependent cell death mechanism characterized by excessive lipid peroxidation, has been implicated in numerous human diseases and organ pathologies. However, current detection methods necessitate invasive tissue sampling to assess lipid peroxidation, making noninvasive detection of ferroptosis in human subjects extremely challenging. In this study, we employed oxidative volatolomics to comprehensively characterize the volatile oxidized lipids (VOLs) produced during...

Read More arrow

Linc01271 promotes lipid synthesis and MASLD/MASH progression via miR-149-3p/RAB35 axis

September 2025

Metabolic associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by hepatocellular injury, inflammation, and fibrosis. Despite advances in understanding its pathophysiology, the molecular mechanisms driving MASH progression remain unclear. This study investigates the role of long non-coding RNA Linc01271 in MASLD/MASH pathogenesis, ant its involvement in the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR signaling pathway....

Read More arrow

Two-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010-2021)

September 2025

CONCLUSIONS: The prevalence of MASLD and associated complications (cirrhosis and liver cancer) increased substantially across the MENA region from 2010 to 2021, with variation across countries.

Read More arrow

Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease

September 2025

CONCLUSIONS: The imbalance between Th17 and T-regulatory immune responses is present not only at cytokine level but also at a cellular level in MASLD. Especially in advanced disease, a higher percentage of IL-17 producing T-cells is coupled with the lower number of T-regulatory cells.

Read More arrow

Sappanone A, a potential natural inhibitor of PI3K, alleviates metabolic dysfunction-associated steatohepatitis in experimental models

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH) affects a large proportion of the global population and is widely regarded as the fastest growing cause of hepatocellular carcinoma. Currently, approved therapeutic strategies for MASH are limited. Therefore, this study used the Connectivity Map (CMap) database to identify a candidate compound for MASH, evaluate its efficacy in experimental models, and explore its mechanism of action. Based on the gene expression profile of GSE126484,...

Read More arrow

The Risk of Gastrointestinal Bleeding with Dual Antiplatelet Therapy in Cirrhotics Undergoing Liver Transplant Evaluation

September 2025

CONCLUSION: Use of DAPT was not associated with an increased risk of GI bleeding or bleeding-related complications in decompensated cirrhotics with coronary artery disease undergoing LT evaluation.

Read More arrow

Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index

September 2025

CONCLUSION: Exercise training leads to MASH resolution, as defined by the MASH-RI at greater rates than standard lifestyle counseling. Future research is needed to determine how best to use the MASH-RI as a therapeutic monitoring tool to gauge response to lifestyle intervention.

Read More arrow

Design, synthesis, and biological evaluation of liver-targeting phosphoric acid thyroid hormone receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH) represents a progressive stage of metabolic dysfunction-associated steatotic liver disease (MASLD) and is characterized by steatosis, inflammation, hepatocyte ballooning, and fibrosis. Resmetirom, a thyroid hormone receptor β (THR-β) agonist, is the first drug approved by the FDA for the treatment of MASH. The beneficial effects of THR-β agonists on lipid levels primarily result from their action on THR-β in the liver, whereas adverse...

Read More arrow

Sclareol mitigates steatosis, inflammation, and fibrosis through the regulation of AMPK/SREBP1/NF-kappaB/TGF-beta pathways in metabolic dysfunction-associated steatohepatitis

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). The increasing burden of MASH and its associated complications is challenging to cure. Our study aims to investigate the therapeutic potential of sclareol in MASH pathogenesis. Huh-7 cells were treated with various concentrations of free fatty acids (FFAs; 200-1200 µM), followed by treatment with sclareol (FFAs; 1200 µM + sclareol; 5 µM to 100 µM)....

Read More arrow

Accidental Fall Revealing an Atypical Presentation of a Rare Disease: A Case of Budd-Chiari Syndrome

September 2025

Budd-Chiari syndrome (BCS) is a rare vascular disorder characterized by hepatic venous outflow obstruction. Polycythemia vera (PV) is a common underlying etiology contributing to BCS. The diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) in this case warrants reconsideration based on recent diagnostic criteria. We report a case of a 53-year-old male patient who presented with weakness, lethargy, and chest pain. A recent fall resulting in a spiral fracture of the thoracic spine...

Read More arrow

Efficacy and Safety of Vitamin E in Adults With Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

September 2025

This systematic review and meta-analysis evaluated the efficacy and safety of vitamin E supplementation in adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). A comprehensive search of PubMed, Cochrane Library, Embase, and Scopus databases was conducted from inception to May 25, 2025, identifying randomized controlled trials comparing vitamin E versus placebo in MASH patients. After screening 752 records, three high-quality...

Read More arrow